The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD candidates with blockbuster potential. According to Reuters, MSD – known as Merck & Co in ...

MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

Enlicitide significantly reduces LDL-C in patients with high cardiovascular risk MSD has announced positive results from its phase 3 CORALreef Lipids trial, showing that enlicitide decanoate, an ...

Adam Piekarski decided to go it alone after more than a decade at BDT & MSD Partners. He’s backing up that bet with a historic unveiling. Derby Lane Partners has amassed $1.8 billion in commitments ...

ST. LOUIS – From a hospital to housing complexes, some of our area’s largest institutions are behind on their utility bills. Thousands of account holders owe more than $100 million owed to the ...

BDT & MSD Partners-backed Alliance Laundry Holdings Inc. filed for an initial public offering, outlining plans to raise equity to pare its debt. The maker of commercial washers and dryers recorded net ...

Allens has advised global merchant bank BDT & MSD Partners on its proposed $1.6 billion investment in Australian-headquartered health, pharmaceuticals and beauty corporation DBG Health. The deal ...

MSD is slashing $3bn (€2.59bn) from its annual spending as it braces for off-brand competition to its Irish-manufactured cancer drug Keytruda, the best-selling medicine in the world. The drugmaker ...

Set 15 of Teamfight Tactics, officially titled K.O. Coliseum, is going live on Wednesday, July 30 with patch 15.1. For this set, your favorite League of Legends champions will face off in an anime ...

Hanmi Pharmaceutical collaborates with Merck (MSD) to evaluate the combination therapy of its immune anticancer drug candidate and MSD's immune anticancer drug "Keytruda" (ingredient name ...

As American Merck (MSD) accelerates its plan to launch the cancer drug Keytruda in a subcutaneous injection (SC) formulation instead of an intravenous injection (IV), a patent dispute has erupted over ...